BioStem Technologies Revenue Growth & History (BSEM)
BioStem Technologies reported $47.5M in revenue for fiscal 2025, a decrease of 31.84% from the previous fiscal year.
View full BioStem Technologies company overviewBioStem Technologies annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $47.5M | −$22.2M | −31.84% |
| 2024 | 2024-12-31 | $69.7M | $53.0M | +317.48% |
| 2023 | 2023-12-31 | $16.7M | $9.8M | +142.69% |
| 2022 | 2022-12-31 | $6.9M | $2.5M | +58.38% |
| 2021 | 2021-12-31 | $4.3M | — | — |
BioStem Technologies quarterly revenue
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.9M | −$3.1M | −27.95% |
| Q1 2026 | 2026-03-31 | $7.6M | −$68.9M | −90.04% |
| Q3 2025 | 2025-09-30 | $10.5M | — | — |
| Q2 2025 | 2025-06-30 | $11.0M | — | — |
| Q1 2025 | 2025-03-31 | $76.6M | — | — |
| Q4 2024 | 2024-12-31 | $102.9M | — | — |
BioStem Technologies revenue growth trends
BioStem Technologies's latest reported quarter, Q2 2026, generated $7.9M in revenue, a decrease of 27.95% year over year.
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review BioStem Technologies source filings ↗Community posts
BioStem secures access to a $40 million equity-purchase facility
BioStem ($BSEM) Technologies entered into a committed equity facility providing potential access to as much as $40 million through share sales to Roth Principal Investments. The company controls whether to draw on the arrangement and intend ...